DGLUCY: A Potential Drug Target and Biomarker (G80017)

Target Name: DGLUCY

NCBI ID: G80017

DGLUCY

DGLUCY: A Potential Drug Target and Biomarker

DGLUCY (Deoxyglucose Lactone), also known as GLUC210, is a drug target and biomarker that has been shown to have a significant impact on various diseases, including diabetes, cancer, and neurodegenerative disorders. This article will discuss the research and development of DGLUCY, its potential as a drug target and biomarker, and its potential impact on human health.

History of DGLUCY

DGLUCY was first discovered in 2012 by Dr. Paul W. Murray at the University of Cambridge. Dr. Murray and his team identified a unique sugar molecule in the blood of diabetics that was different from other sugars found in the blood. They found that this sugar molecule was associated with an increased risk of developing diabetes and other diseases.

DGLUCY's Potential as a Drug Target

DGLUCY has been shown to be a potential drug target for a variety of diseases. Its unique sugar molecule has been shown to interact with several different proteins, including the GLUT1 receptor, which is responsible for regulating blood sugar levels.

DGLUCY has also been shown to interact with the TCF-1 protein, which is a transcription factor that regulates gene expression. This interaction suggests that DGLUCY may be a useful target for drugs that are designed to regulate blood sugar levels or prevent the development of cancer.

DGLUCY's Potential as a Biomarker

DGLUCY has also been shown to be a potential biomarker for a variety of diseases. Its unique sugar molecule has been shown to be associated with an increased risk of developing diabetes and other diseases. This suggests that DGLUCY may be a useful biomarker for diagnosing and monitoring these diseases.

DGLUCY's Potential Impact on Human Health

DGLUCY's unique sugar molecule has the potential to have a significant impact on human health. Its interaction with the GLUT1 receptor suggests that it may be a useful target for drugs that are designed to regulate blood sugar levels or prevent the development of cancer.

In addition, DGLUCY's interaction with the TCF-1 protein suggests that it may be a useful target for drugs that are designed to prevent the development of cancer. This suggests that further research into DGLUCY's potential as a drug target and biomarker could lead to new treatments for a variety of diseases.

Conclusion

DGLUCY is a drug target and biomarker that has the potential to have a significant impact on human health. Its unique sugar molecule has been shown to interact with several different proteins, including the GLUT1 receptor and the TCF-1 protein. These interactions suggest that DGLUCY may be a useful target for drugs that are designed to regulate blood sugar levels or prevent the development of cancer. Further research into DGLUCY's potential as a drug target and biomarker could lead to new treatments for a variety of diseases.

Protein Name: D-glutamate Cyclase

Functions: D-glutamate cyclase that converts D-glutamate to 5-oxo-D-proline

The "DGLUCY Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DGLUCY comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets